This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antoniazzi, F. Articles by Tatò, L. Search for Related Content PubMed PubMed Citation Articles by Antoniazzi, F. Articles by Tatò, L.

Prevention of Bone Demineralization by Calcium Supplementation in Precocious Puberty during Gonadotropin-Releasing Hormone Agonist Treatment

Clinica Pediatrica e Istituto di Medicina Interna (F.B., E.G.), Università degli Studi di Verona, Verona, Italy

Address all correspondence and requests for reprints to: Dott. Franco Antoniazzi, Clinica Pediatrica Università di Verona, Policlinico Borgo Roma, I-37134 Verona, Italy. E-mail: francoa{at}borgoroma.univr.it

We have previously demonstrated a negative impact on peak bone mass in girls with precocious puberty treated with GnRH agonist (GnRHa). Several studies have shown that a high calcium intake positively influences bone mass in prepubertal girls and leads to a higher peak bone mass. The aim of this study was to evaluate the effect of calcium supplementation in girls with precocious puberty during GnRHa treatment.

Forty girls affected by true central precocious puberty and treated with the GnRHa triptorelin were studied for 2 yr. After diagnosis, the patients were randomly assigned to three groups: group A, treated only with GnRHa; group B, treated for 12 months solely with GnRHa and then supplemented with calcium gluconolactate/carbonate (1 g calcium/day in two doses) for 12 months; and group C, treated from the beginning with combined GnRHa and calcium.

Bone mineral density (BMD) at the lumbar spine was measured by dual energy x-ray absorptiometry at the beginning of the study and after 12 and 24 months and was expressed as the calculated true volumetric density (BMDv) in milligrams per cm³.

Group A showed a decrease in absolute BMDv levels, in SD score for chronological age (CA), and even more in SD score for bone age (BA). Group B showed the same behavior during the first year, but this trend was reversed in the second year, when calcium supplementation was added to GnRHa treatment. Group C showed an increase in absolute BMDv levels and in SD score for CA and BA. BMDv variations (expressed as absolute values, SD score for CA, and SD score for BA) became statistically significant at 24 months between groups C and A (P = 0.036, P = 0.032, and P = 0.025, respectively).

The behavior of the lumbar spine BMDv in the three groups is consistent with a positive effect of calcium supplementation during GnRHa treatment. In calcium-supplemented patients, the normal process of bone mass accretion at puberty is preserved despite GnRHa treatment. Therefore, the reduction in BMD during GnRHa treatment in girls with precocious puberty is at least completely reversible and preventable if calcium supplementation is associated from the beginning.

This article has been cited by other articles:

				A. M. Pasquino, I. Pucarelli, F. Accardo, V. Demiraj, M. Segni, and R. Di Nardo Long-Term Observation of 87 Girls with Idiopathic Central Precocious Puberty Treated with Gonadotropin-Releasing Hormone Analogs: Impact on Adult Height, Body Mass Index, Bone Mineral Content, and Reproductive Function J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 190 - 195. [Abstract] [Full Text] [PDF]

				C.A.A. Silva and H.I. Brunner Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus Lupus, August 1, 2007; 16(8): 593 - 599. [Abstract] [PDF]

				F. Antoniazzi, G. Zamboni, F. Bertoldo, S. Lauriola, F. Mengarda, A. Pietrobelli, and L. Tato Bone Mass at Final Height in Precocious Puberty after Gonadotropin-Releasing Hormone Agonist with and without Calcium Supplementation J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1096 - 1101. [Abstract] [Full Text] [PDF]

				J. Z. Ilich and J. E. Kerstetter Nutrition in Bone Health Revisited: A Story Beyond Calcium J. Am. Coll. Nutr., June 1, 2000; 19(6): 715 - 737. [Abstract] [Full Text] [PDF]

				Long-Term Outcome after Depot Gonadotropin-Releasing Hormone Agonist Treatment of Central Precocious Puberty: Final Height, Body Proportions, Body Composition, Bone Mineral Density, and Reproductive Function J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4583 - 4590. [Abstract] [Full Text]